Verona Pharma PLC- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於公司

公司簡介

公司代碼VRNA

公司名稱Verona Pharma PLC

上市日期Mar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

員工數量209

證券類型Depository Receipt

年結日Mar 30

公司地址Riverside

城市LONDON

上市交易所NASDAQ Global Market Consolidated

國家United Kingdom

郵編SE1 2RE

電話442032834200

網址https://www.veronapharma.com/

公司代碼VRNA

上市日期Mar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. David S. Zaccardelli, Pharm.D.

President, Chief Executive Officer, Executive Director

175.14K

-66.98%

Mr. Mark W. Hahn, CPA

Chief Financial Officer

61.24K

-90.96%

Mr. Andrew Fisher

General Counsel

14.74K

--

Mr. Vikas Sinha, CPA

Non-Executive Independent Director

11.76K

-84.20%

Dr. Mahendra G. Shah, Ph.D.

Non-Executive Independent Director

11.68K

-84.01%

Ms. Lisa Deschamps

Non-Executive Independent Director

10.61K

-84.92%

Mr. Michael Austwick

Non-Executive Independent Director

1.59K

--

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

--

Ms. Christina Ackermann

Non-Executive Independent Director

--

Dr. Martin William Edwards, M.D.

Non-Executive Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. David S. Zaccardelli, Pharm.D.

President, Chief Executive Officer, Executive Director

175.14K

-66.98%

Mr. Mark W. Hahn, CPA

Chief Financial Officer

61.24K

-90.96%

Mr. Andrew Fisher

General Counsel

14.74K

--

Mr. Vikas Sinha, CPA

Non-Executive Independent Director

11.76K

-84.20%

Dr. Mahendra G. Shah, Ph.D.

Non-Executive Independent Director

11.68K

-84.01%

Ms. Lisa Deschamps

Non-Executive Independent Director

10.61K

-84.92%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 9月6日週六

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

其他

74.07%

持股股東

佔比

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

其他

74.07%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

26.68%

Hedge Fund

26.26%

Investment Advisor

18.32%

Private Equity

10.42%

Venture Capital

4.96%

Individual Investor

4.89%

Research Firm

4.38%

Family Office

1.17%

Pension Fund

0.15%

其他

2.77%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

423

82.86M

96.18%

-3.71M

2025Q1

406

83.91M

98.59%

+940.31K

2024Q4

326

71.46M

84.46%

-16.29M

2024Q3

290

72.06M

88.66%

-13.37M

2024Q2

265

71.81M

88.57%

-10.49M

2024Q1

244

72.12M

89.24%

-7.07M

2023Q4

230

69.67M

87.15%

-7.79M

2023Q3

210

67.04M

84.35%

-7.14M

2023Q2

205

65.57M

82.53%

-8.85M

2023Q1

188

68.22M

86.63%

-3.18M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

5.52M

6.48%

+3.85M

+230.91%

Mar 31, 2025

Perceptive Advisors LLC

6.56M

7.71%

+171.23K

+2.68%

Mar 31, 2025

Darwin Global Management Ltd

3.92M

4.61%

+3.11M

+384.08%

Mar 31, 2025

Frazier Life Sciences Management, L.P.

3.46M

4.06%

+73.90K

+2.18%

Mar 31, 2025

Ali (Behbahani)

3.19M

3.75%

+3.19M

--

Jan 16, 2025

RTW Investments L.P.

2.85M

3.35%

+1.03M

+56.44%

Mar 31, 2025

Eventide Asset Management, LLC

2.89M

3.4%

-238.69K

-7.62%

Mar 31, 2025

New Enterprise Associates (NEA)

2.69M

3.16%

-1.40M

-34.18%

Mar 31, 2025

Summit Partners Public Asset Management, LLC

2.32M

2.73%

+421.09K

+22.14%

Mar 31, 2025

持股ETF

更新時間: 9月6日週六

機構名稱

佔比

AltShares Merger Arbitrage ETF

4.25%

First Trust International Equity Opportunities ETF

2.06%

iShares Biotechnology ETF

0.5%

Fidelity Nasdaq Composite Index ETF

0.03%

AltShares Merger Arbitrage ETF

佔比4.25%

First Trust International Equity Opportunities ETF

佔比2.06%

iShares Biotechnology ETF

佔比0.5%

Fidelity Nasdaq Composite Index ETF

佔比0.03%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Verona Pharma PLC

106.690USD

Verona Pharma PLC

106.690

概覽

公司

財務

分析